Skip to main content
TipRanks
Go Ultimate75% OFF

PetVivo Holdings (PETV) AI Stock Analysis

35 Followers
PETV

PetVivo Holdings

(Other OTC:PETV)

Select Model
Rating:44Neutral
Price Target:$0.29▼(-3.00% Downside)
Action:reiterated
Date:11/20/26

PetVivo Holdings is a highly distressed micro-cap stock facing critical liquidity and solvency risks, which heavily weigh down its overall score. The complete lack of operational profitability, negative equity, and a deeply entrenched technical downtrend are the primary factors driving this bearish outlook. While the latest earnings report indicates slight margin improvements and recent board additions offer strategic value, the company's survival heavily depends on successfully securing imminent external financing to mitigate its severe cash burn.

Positive Factors
High-margin core productSpryng’s high product margin gives PetVivo a stronger foundation for improving gross profit as sales mix shifts toward the flagship offering. If adoption expands, this mix benefit could support operating leverage and make future revenue growth more economically valuable.
Negative Factors
Deep and persistent unprofitabilityThe company’s current revenue base is far too small to cover its operating structure, producing substantial losses despite strong gross margins. Until scale improves materially or costs decline further, profitability remains uncertain and additional growth may continue requiring outside capital.

PetVivo Holdings (PETV) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%PETV-76.56%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$11.39M
Dividend Yield
―
Average Volume (3M)
18.87K
Price to Earnings (P/E)
-1.2
Beta (1Y)
0.10
Revenue Growth
-22.55%
EPS Growth
34.73%
Country
US
Employees
22
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

PetVivo Holdings Business Overview & Revenue Model

Company Description

PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its...

How the Company Makes Money

PetVivo primarily makes money by selling its companion-animal joint health product(s) to the veterinary market. Revenue is generated from product sales made through veterinary channels (e.g., veterinary clinics and/or distribution partners) where vet...

PetVivo Holdings Earnings Call Summary

Earnings Call Date:Aug 14, 2026(Q1-2027)|% Change Since:-55.88%|Next Earnings Date:Aug 14, 2025
Earnings Call SentimentNeutral

The call communicated meaningful commercial, product and technological progress — including double-digit revenue growth, margin improvement, international regulatory recognition, strong AI beta results, and strategic M&A and partnership activity. However, the company remains small in absolute revenue, continues to report operating and net losses, has a tight cash balance ($123k) and depends on pending financing and grants (including a referenced $5M raise to close the PBM acquisition). The positives around product validation, high-margin pipeline opportunities and operational improvements are balanced by liquidity, financing and execution risks.

Positive Updates

Revenue Growth
Total revenues increased 13% year-over-year to $338,000 and rose 33% versus the prior quarter, driven by stronger sales of flagship Spryng.

Negative Updates

Weak Absolute Revenue Scale and Ongoing Losses
Despite revenue growth, absolute quarterly revenue remains small at $338,000 and the company reported a net loss of $1.7 million and operating loss of $1.6 million for the quarter.

Company Guidance

Management guided continued momentum for fiscal 2027, highlighting Q1 revenue up 13% YoY to $338K (up 33% sequentially) — $276K via distributors and $62K direct — with gross profit $223K (66% margin) and flagship Spryng margin ~90.3%; total operating expenses declined 10% to $1.8M (R&D -31%, G&A -9%, S&M +2%) producing an operating loss of $1.6M and a net loss of $1.7M ($0.05/share), an ~30% improvement from $2.3M ($0.10) a year ago. Cash used in operations fell ~40% to ~$966K (a $668K reduction), ending cash was $123K, and management expects completion of a $1.35M subscription commitment and has discussed a ~$5M capital raise tied to the PBM acquisition (expected to close soon). They forecast higher revenue margins going forward, Health Canada commercialization with Canadian distributors anticipated in 1–2 months, a government grant decision before year‑end, PetVivo.ai commercial launch in the coming months after beta results showing a 50–90% reduction in customer acquisition cost (from $80–$400 to <$43) and 97% diagnostic accuracy, and a new recurring PetVivo.ai revenue stream with projected 80–90% gross margins.

PetVivo Holdings Financial Statement Overview

Summary

Scores the minimum due to severe profitability and solvency risks. Despite stable gross margins, the company faces declining TTM revenue, negative stockholders' equity (-$159k), and chronic cash burn with -$4.19M in operating cash flow.

Income Statement

15Very Negative

Balance Sheet

10Very Negative

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.09M1.14M1.13M968.71K917.16K115.59K
Gross Profit767.36K754.75K994.86K739.53K390.35K-85.57K
EBITDA-8.26M-8.86M-7.69M-10.49M-8.62M-4.99M
Net Income-8.72M-10.47M-8.40M-10.96M-8.70M-4.94M
Balance Sheet
Total Assets2.15M3.58M9.34M3.12M2.44M7.43M
Cash, Cash Equivalents and Short-Term Investments16.29K350.78K377.69K87.40K475.31K6.11M
Total Debt1.40M376.16K2.90M1.37M345.33K332.85K
Total Liabilities2.31M1.38M5.12M2.43M1.71M1.44M
Stockholders Equity-159.09K2.20M4.22M685.95K725.02K5.99M
Cash Flow
Free Cash Flow-4.20M-6.12M-5.89M-7.73M-7.22M-4.36M
Operating Cash Flow-4.19M-6.11M-5.32M-7.42M-6.79M-4.17M
Investing Cash Flow-29.21K11.80K-563.43K-309.10K-423.93K-183.18K
Financing Cash Flow3.54M6.07M6.03M7.34M1.59M10.44M

PetVivo Holdings Technical Analysis

Technical Analysis SentimentNegative
Last Price0.30

Price Trends

50DMA0.68Negative
100DMA0.69Negative
200DMA0.73Negative

Market Momentum

MACD-0.10Positive
RSI25.90Positive
STOCH6.84Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PETV, the sentiment is Negative. The current price of 0.30 is below the 20-day moving average (MA) of 0.57, below the 50-day MA of 0.68, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 25.90 is Positive, neither overbought nor oversold. The STOCH value of 6.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PETV.

PetVivo Holdings Risk Analysis

PetVivo Holdings disclosed 35 risk factors in its most recent earnings report. PetVivo Holdings reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Supply Chain DisruptionsQ3, 2025
2.Reduced SpendingQ3, 2025
3.Reduced Consumer ConfidenceQ3, 2025

PetVivo Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PETV against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
BVSBVS75Outperform$838.40M11.7627.23%―3.87%623.68%
KIDSKIDS61Neutral$848.85M-22.73-9.91%―16.15%27.21%
ANIKANIK54Neutral$177.89M-102.55-1.28%―9.42%94.37%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TELATELA44Neutral$32.84M-0.98425.91%―1.46%15.79%
PETVPETV44Neutral$11.56M-1.18-514.53%―-22.55%34.73%
XTNTXTNT39Underperform$30.35M-1.84-36.21%―-24.44%-1012.80%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%PETVANIKXTNTKIDSTELABVSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PETV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PETVPetvivo Holdings Inc0.30-0.78-72.22%
ANIKAnika Therapeutics, Inc.13.283.4034.41%
XTNTXtant Medical Holdings Inc0.22-0.41-65.22%
KIDSOrthopediatrics Corp32.5114.6682.13%
TELATela Bio, Inc.0.73-0.44-37.95%
BVSBioventus, Inc.9.952.7137.43%

PetVivo Holdings Corporate Events

Business Operations and StrategyExecutive/Board Changes

PetVivo Holdings Announces Board Changes and New Director

Positive
Sep 22, 2026

On September 22, 2026, PetVivo Holdings announced that life sciences executive Michael K. Handley joined its Board of Directors, filling the vacancy created by the same-day resignation of director Joseph Jasper, which the company said did not stem fr...

Business Operations and StrategyExecutive/Board Changes

PetVivo Holdings Adds Veteran Leader to Board

Positive
Sep 22, 2026

On September 22, 2026, PetVivo Holdings, Inc. announced that veterinarian and healthcare executive Jaime K. Pickett joined its Board of Directors, filling the vacancy created by the resignation of director Diane Levitan, whose departure was not due t...

Business Operations and StrategyRegulatory Filings and Compliance

PetVivo Holdings Updates Investor Presentation Under Regulation FD

Neutral
Aug 20, 2026

PetVivo Holdings has furnished an investor presentation as part of a Form 8-K filing, outlining information it expects to use in upcoming appearances at investor conferences and other forums. The materials are being shared under SEC Regulation FD, si...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026